Company ProfilePremium

Albert David Limited

Company Profile Analysis

Tickers: ALBERTDAVD.NS, 524075.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Albert David Limited - Company showcase

Year Founded & Workforce

1938

Albert David Limited logo

Albert David Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Albert David Limited Overview

Albert David Limited is an 88-year-old, promoter-controlled Indian branded-generics and specialty-formulation company with a niche franchise. Its flagship, Placentrex, is described by CARE Ratings as the only human-placenta-derived pharmaceutical in India developed through indigenous research, and it is protected by a process patent. The company also makes intravenous infusions (large-volume parenterals in glass and form-fill-seal plastic bottles) at Ghaziabad, oral and topical formulations and herbal products at Kolkata, and sodium stibogluconate (SSG) for kala-azar, for which it is an authorised WHO supplier. With FY26 revenue of INR 333.6 crore, it is a micro-cap at the edge of the top-100 Indian pharma companies. It is effectively debt-free and holds about INR 259 crore of cash and liquid investments, but it has stagnated operationally: revenue has fallen two years running and operating margins collapsed from about 13% to low single digits after an expensive field-force expansion. A new CEO, Amit Mahla, ex-Cipla, Sun and JB, took charge in May 2026 to engineer a turnaround.


Company's own description

In its corporate literature and on its letterhead, Albert David describes itself as "Manufacturers of Allopathic & Herbal Formulations, I.V. Infusions & Medical Disposables" under the tagline "Imagine Inspire Deliver" [BSE/NSE filings, Feb 2026 and Jul 2026]. Its stated principal business is the manufacture and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs for domestic sale and export, along with disposable syringes and needles and a range of bulk drugs [company profile reproduced by Arihant Capital and Kotak Securities, derived from AR]. The company also says it works with academic institutes, namely the Indian Institute of Chemical Biology (CSIR) and the Department of Biotechnology at Calcutta University, on outsourced research [company website via Screener].

Independent characterisation

Albert David is best understood as three businesses sharing one listed entity and one sales and distribution infrastructure:

  1. Specialty branded formulations, led by Placentrex. This is a prescription franchise built on a unique biologic-derived product (human placental extract in injection and gel forms) with no direct domestic substitute. Placentrex contributed 26% of FY26 revenue (20% in FY25) according to CARE [CARE Jul-26]. Press coverage of the FY26 annual report gives "over 30%", which may reflect a different denominator or include line extensions. The top five products made up 45% of FY26 sales (39% in FY25) [CARE Jul-26], which shows high and rising concentration.

  2. Hospital and institutional parenterals (IV fluids). These are large-volume parenterals made at Ghaziabad since 1981 in glass and polyethylene form-fill-seal bottles, historically with amino-acid infusions under a technical collaboration with Morishita Pharmaceuticals (an Ajinomoto subsidiary) [corporate history, Kotak/Arihant profiles]. This is a high-volume, low-price, commoditised category dominated by much larger players.

  3. Herbal/OTC-adjacent and anti-infective/tropical medicine products. These include herbal brands such as Adliv (hepatoprotective) and Siotone (adaptogen), and SSG for leishmaniasis (kala-azar), supplied to WHO for use in African countries [CARE Jul-26; investyadnya/medicaldialogues profiles].

Business and revenue model

DimensionCharacterisationEvidence / source
Product vs serviceAlmost entirely product revenue from manufactured and traded pharmaceuticals; no material service, subscription or licensing revenue disclosedSingle segment "Pharmaceuticals" [Q4 FY26 filing]
Manufactured vs traded mixNot publicly disclosed in the sources reviewed (Screener lists a "manufactured goods share" KPI behind a paywall)—
ChannelTrade distribution through carrying-and-forwarding agents (CFAs) and stockists; 2,193 CFA-linked stockists at 31 Mar 2026, down from 2,338 a year earlier[CARE Jul-26]
Customer typesMajor pharmaceutical distributors in India (no single customer above 5% of net sales; top five clients 13% of FY26 sales vs 17% in FY25); hospitals and institutions for IV fluids; WHO (SSG); export buyers[CARE Jul-26]
Promotion modelPrescription promotion through a medical-representative field force, expanded in FY25–FY26 with new divisions[AR FY25; AR FY26]
Geographic focusStrongest in eastern and northern India, with marketing offices in Mumbai, Kolkata, Lucknow and Patna; expansion into southern and western India under way[CARE Jul-26]
ExportsGuyana, Philippines and Myanmar named in 2026; historically a much wider list of African, CIS and Latin American markets[CARE Jul-26; historical profiles]
Value-chain positionFormulator and marketer, with some historical bulk-drug capability (the Kalyani bulk-drug unit commissioned in 1990; current status not confirmed). Imports key inputs (lactose, glass bottles, amino acids) from Finland, China, Austria and other European countries[CARE Jul-26; corporate history]

End-markets served

Indian Pharmaceutical Market (IPM), retail prescription: wound healing and tissue repair, orthopaedics and pain, gynaecology, hepatology, nutrition and vitamins, and anti-infectives.

Hospital and institutional market: IV fluids, parenteral nutrition and critical care.

Global public-health procurement: WHO-linked supply of SSG for visceral leishmaniasis.

Herbal and wellness: adaptogens and hepatoprotectives.

Strategy

Stated strategic themes (from annual reports)

AR FY22: focus on growing presence "organically as well as inorganically, both in the domestic and the international market", with new launches (Evacure, C3H) expected to add to revenue and profits.

AR FY25: the year was described as "challenging" and "strategic … in terms of future and stability planning". Under CEO Kunte the company "invested in creating new divisions and strengthening the field force … for future growth".

AR FY26: strengthening the product line and widening the customer base, with Placentrex as the primary growth lever; continued R&D on Placentrex bioconstituents with IIT Kharagpur; and field-force investment, which management said affected current results.

Strategic initiatives (last 24 months)

InitiativeTimingDescriptionStatus / evidence
Field-force and division expansionFY24–FY26More medical representatives, new divisions, and higher marketing spend in southern and western IndiaImplemented; caused the FY25 margin collapse; partly rationalised in FY26–Q1 FY27 (lower employee costs) [CARE Jul-26; Q1 FY27 results]
Placentrex scientific validationFY26 onwardsBioconstituent mapping with IIT KharagpurOngoing [AR FY26]
Leadership transitionDec 2025 – Jun 2026New CEO Amit Mahla, with transformation and portfolio-integration experienceCompleted; strategy under the new CEO not yet articulated publicly in an investor presentation
Cost disciplineFY26–FY27Lower employee and selling and distribution costsPBILDT margin up to 2.88% (FY26) and about 10% in Q1 FY27 [CARE Jul-26; Screener]
CapexFY26CWIP rose to INR 21 croreProject not specified; CARE expects no significant capex near term
Board strengtheningNov 2024 – Aug 2025Two new independent directorsCompleted

Medium-term targets and guidance

Albert David does not publish quantitative guidance, hold earnings calls, or publish investor presentations (no transcripts identified). The only quantified external benchmarks come from CARE's rating sensitivities:

Upgrade trigger: total operating income above INR 500 crore with PBILDT margin above 15% on a sustained basis.

Downgrade triggers: liquidity below INR 100 crore; net debt / gross cash accruals above 0.25x; or debt-funded capex pushing gearing above 0.20x.

ESG and sustainability commitments

No public emissions targets or sustainability-linked commitments were identified.

Products & Services

Disclosure limitation: Albert David does not publish a complete brand-by-brand catalogue with specifications or pricing in its filings. Online pharmacy aggregators list roughly 155–162 SKUs marketed by the company (Truemeds). The catalogue below is built from filings, rating reports and historical company profiles. Pricing in India is set by trade price/MRP and, for scheduled formulations, by NPPA/DPCO ceilings; brand-level prices are not disclosed by the company.

All products fall within the single Pharmaceuticals segment and are grouped below by business line.

Specialty biologic-derived formulations

BrandDescriptionTarget customerLaunch / statusNotes
Placentrex (injection)Aqueous extract of human placenta; the company's flagship. CARE describes it as India's only human-placenta-based product developed through indigenous research, protected by a process patentOrthopaedics, surgeons, dermatologists, gynaecologists and ophthalmologists (wound and tissue healing, chronic inflammatory conditions)Long-established; launch year not disclosed26% of FY26 revenue [CARE Jul-26]; the leading growth lever according to the AR FY26 summary
Placentrex (gel)Topical placental-extract gel for wound and burn healingSurgeons, dermatologists, burns units, retailLong-establishedGel form confirmed by product listings; revenue split vs injection not disclosed
Placentrex R&D extensionBioconstituent mapping of placental extract with IIT Kharagpur—Ongoing (FY26)Aimed at scientific validation and possible new indications [AR FY26 summary]

Anti-infective / tropical medicine

BrandDescriptionTarget customerNotes
Sodium Stibogluconate (SSG) injectionPentavalent antimonial for visceral leishmaniasis (kala-azar)WHO procurement for African countries; endemic-region health systemsAlbert David is an authorised WHO supplier [CARE Jul-26]

Parenterals / IV infusions (Ghaziabad)

Product familyDescriptionTarget customerNotes
Large-volume parenterals in glass bottlesIV fluids for fluid and electrolyte replacementHospitals, nursing homes, institutional tendersSince 1981 [CARE Jul-26]
LVPs in polyethylene form-fill-seal bottlesIV fluids in blow-fill-seal plastic containersHospitals, institutionsFFS capacity expanded with a 1990s rights issue [corporate history]
Amino-acid infusionsParenteral nutrition; technology originally from Morishita/AjinomotoCritical care, surgery, ICUCollaboration since 1987
Ophthalmic productsEye preparations made at GhaziabadOphthalmologists, retailCapability confirmed [CARE Jul-26]; brands not itemised

The specific IV fluid SKUs (for example dextrose, sodium chloride or Ringer's lactate) are standard industry products, but the company does not publish its list. Volumes and capacities are not publicly disclosed in the sources reviewed.

Herbal formulations

BrandDescriptionTarget customerNotes
AdlivHerbal hepatoprotectiveGeneral physicians, gastroenterologists, retail[Historical company profile]
Siotone (capsule)Herbal adaptogen; historically described as the only adaptogen indicated for stressGPs, psychiatrists, consumers[Historical company profile]
Sio-range extensions (e.g. "Siooxy", planned in 2002-03)Herbal / nutraceutical line extensions—Planned launch noted historically

Nutrition, vitamins and general formulations (Kolkata and Ghaziabad)

BrandDescriptionLaunch yearVerification status
Sioplex (capsules)Multivitamin supplement—Listed by Truemeds as a popular product
Intecar (capsules)—2,003Launch confirmed
Nimeril-T—2,003Launch confirmed
Evict—2,003Launch confirmed
Alrof-50—2,003Launch confirmed
Adlin—2,003Launch confirmed
Slozin—2,003Launch confirmed
Alamin-FeZ—2,004Launch confirmed
Pansure—2,004Launch confirmed
Evacure—FY2022Launch confirmed [AR FY22]
C3H—FY2022Launch confirmed [AR FY22]

Medical disposables and bulk drugs

Product familyDescriptionStatus
Disposable syringes and needlesSingle-use injection devicesListed in the business description and letterhead ("Medical Disposables"); current scale not disclosed
Bulk drugs (APIs)Range of bulk drugs, historically from the Kalyani unitCurrent status of the Kalyani unit not confirmed in 2026 sources

Recent launches (FY25–FY27)

The FY25 and FY26 annual reports refer to new divisions and "strengthening its product line and widening its clientele", but no specific new brand launches for FY25–FY27 were identified. Not publicly disclosed.

Financial Narrative

Basis: standalone, Ind AS, INR crore. FY22–FY24 figures are from Screener and the annual reports; FY25–FY26 from the Directors' Reports [AR FY25, AR FY26] and the CARE release [CARE Jul-26]. Gross profit uses StockAnalysis's definition (revenue minus cost of materials and traded goods).

Income statement

Notes:

  • The CARE vs Screener EBITDA gap in FY25–FY26 comes from classifying certain income and expense items (for example forex gains or losses and miscellaneous operating income) inside or outside operating profit. The Directors' Report EBITDA, which includes other income, is 32.61 (FY25) and 12.92 (FY26) [AR FY26].

  • FY25 PBT includes about INR 18.92 crore of non-cash fair-value gains on investments, which CARE calls "exceptional"; the equivalent figure in FY26 was INR 0.63 crore [CARE Jul-26].

  • FY22 and FY23 tax figures are derived from PBT minus PAT.

  • DPS: FY24 (INR 11.50) is derived from the INR 656.32 lakh dividend paid in FY25 ÷ 57.07 lakh shares. FY25 and FY26 (INR 5) are confirmed [AR FY25; AR FY26]. FY22 and FY23 (INR 9) are derived from Screener payout ratios (15% and 14%) and are unconfirmed; verify against the annual reports.

  • EPS sources: [AR FY25] for FY24–FY25; [AR FY26] for FY26; [Screener] for FY22–FY23 (FY23 shown as 63.38 on Screener and 63.39 on TipRanks).

Quarterly trajectory (most recent five quarters)

Sources: [Q1 FY27 results; Q4 FY26 filing; Screener; Equitybulls]. Q2 and Q3 figures are rounded from Screener.

Discrepancy: some aggregators (e.g. INDmoney) report Q4 FY26 "revenue" as INR 61.03 crore. That number is total income (revenue of 85.86 plus negative other income of -24.84), not revenue from operations.

Q1 FY27 detail: employee benefits expense fell to INR 25.55 crore from INR 28.43 crore a year earlier, while cost of materials rose to INR 18.33 crore from INR 13.25 crore, consistent with higher volumes. Tax expense was INR 3.80 crore, including a prior-year credit of INR 2.35 crore [Q1 FY27 results].

Balance sheet

Source: [Screener, standardised from AR]. Other items:

Debt split: borrowings are entirely short-term working-capital or overdraft facilities, largely overdraft drawn against 100% cash margin for interest-rate arbitrage. No term loans have been taken in six years [CARE Jul-26]. Long-term debt is therefore nil in every year.

Cash and liquidity (31 Mar 2026): cash and bank fixed deposits of INR 34.10 crore plus liquid mutual funds and bonds of INR 225.05 crore, a total of INR 259.15 crore [CARE Jul-26].

Net debt (31 Mar 2026): 30 − 259.15 = −INR 229 crore (net cash). Equivalent full liquidity data for earlier years is not available in the reviewed sources, but the investment book of INR 183–273 crore in each year implies the company has been in a net-cash position throughout.

Goodwill and intangibles: not separately material; not publicly disclosed in reviewed summaries.

Working capital: current ratio 2.11x at 31 Mar 2026 [CARE Jul-26]. Screener's working-capital days: -34 (FY22), 14 (FY23), -13 (FY24), 6 (FY25), 1 (FY26).

Retained earnings: INR 24,909.31 lakh (FY25) → INR 24,796.30 lakh (FY26) [AR FY26].

Cash flow

Source: [Screener]. Other items:

Free cash flow definition: Screener derives FCF from CFO less net capex; small definitional differences from CFO minus gross capex are possible.

Dividends paid in cash: INR 6.56 crore (FY25) and INR 2.85 crore (FY26) [AR FY26]. Earlier years are not separately verified.

Buybacks: none in FY22–FY26.

Cash accruals (gross): INR 6.48 crore (FY25) and INR 6.37 crore (FY26) [CARE Jul-26].

Key ratios

Notes:

  • ROE and ROA are computed by the analyst from Screener's balance-sheet data, using FY21 equity of INR 245 crore and FY21 assets of INR 341 crore as opening balances.

  • ROIC: with the capital base dominated by investments (about 47% of assets in FY26), operating ROIC on operating capital (net fixed assets plus CWIP plus net working capital, roughly INR 150–180 crore) was about 15–18% after tax in FY22–FY24 and negative in FY25–FY26. This is an analyst approximation and not disclosed.

  • The FY22–FY24 PBILDT/interest figures are derived from Screener operating profit divided by finance cost; FY25–FY26 are CARE's figures.

  • Net debt / EBITDA is not meaningful because the company holds net cash in every year; for FY26, net cash is about 24x CARE PBILDT.

  • CARE reports total debt to gross cash accruals of 1.90x (FY25) and 4.65x (FY26).

Commentary on trends, inflections and drivers

FY22–FY24: steady compounding with a treasury kicker. Revenue recovered strongly from the COVID-hit FY21 (INR 247 crore) to INR 362 crore by FY24. Gross margin held at 63–65%, which reflects the premium, low-competition economics of Placentrex. Operating margins were stable at about 13%. FY24 earnings were roughly doubled by INR 58 crore of other income, almost certainly mark-to-market and realised gains on the INR 273 crore investment portfolio during a buoyant Indian equity and debt market. Reported FY24 ROE of 21.7% therefore overstates core operating returns; excluding about INR 43 crore of incremental other income, PAT would have been closer to INR 42 crore and ROE about 12%.

FY25: the strategic-investment shock. Under CEO Umesh Kunte (appointed February 2023), the company invested heavily in new divisions and field-force expansion to break out of its eastern and northern stronghold [AR FY25; CARE Jul-26]. Gross margin actually improved to 66.4%, so the damage was below the gross line: operating expenses excluding COGS rose about 20% to INR 226.5 crore while revenue fell 4.6%. Operating margin collapsed from 13% to about 1%. PBT of INR 25.2 crore was flattered by an INR 18.9 crore non-cash fair-value gain. Working capital deteriorated sharply, with inventory days rising from 126 to 201, which pushed operating cash flow negative (−INR 28 crore) for the first time in more than a decade.

FY26: a partial cost reset and treasury volatility. Revenue fell another 3.5%. The second half recovered: Q3 FY26 revenue was +8.2% YoY and Q4 FY26 +14.6% YoY on revenue from operations [TheCompanyCheck quarterly series]. CARE notes PBILDT margin improving from 1.17% to 2.88% on lower employee and selling costs. However, a −INR 24.8 crore other-income swing in Q4 FY26 (investment mark-downs), higher depreciation (INR 9.8 crore, as the CWIP build-up to INR 21 crore began to be capitalised) and an INR 2.6 crore finance cost on overdrafts produced a full-year net loss of INR 1.49 crore, the company's first annual loss in the period reviewed. Management attributed the weak result to field-force investments intended to support future growth.

Q1 FY27: a genuine operating inflection, magnified by treasury. Revenue of INR 101.3 crore (+43.6% YoY) was the highest quarterly revenue in the dataset. Operating margin recovered to about 10%, and employee costs fell 10% YoY despite the higher sales, which suggests the field force has been rationalised under the new CEO. Even so, about 78% of Q1 PBT (INR 28.0 crore of other income out of INR 35.8 crore) came from the treasury book. The quality of earnings therefore remains heavily dependent on financial markets.

Structural observations.

  1. Albert David is a "pharma company wrapped around a fund": investments of INR 243 crore exceed the entire market capitalisation net of operating assets.

  2. Gross margins of about 65% are high for an Indian branded-generics micro-cap, but operating leverage is poor because of a sub-scale revenue base for a national field force.

  3. Working capital, especially inventory, is the main operating cash-flow risk.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Pharmaceuticals segment revenue (INR Cr)

362.46345.77333.60

YoY growth (%)

6.1-4.6-3.5

Share of total revenue (%)

100100100

Segment profit before tax (INR Cr)

97.2925.230.52

PBT margin (%)

26.87.30.2

Operating profit before other income (INR Cr)

4736

Operating margin (%)

13.00.91.7

Revenue by Segment (%)

MetricFY2025FY2026

Placentrex share of revenue (%)

2026

Top-5 products share of sales (%)

3945

Top-5 customers share of net sales (%)

1713

CFA-linked stockists (count, at year end)

2,3382,193

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

313.51341.56362.46345.77333.60

Revenue growth (%)

26.78.96.1-4.6-3.5

Gross profit (INR Cr)

198.6217.5236.1229.5219.7

Operating expenses excl. COGS and D&A (INR Cr)

157.6173.5189.1226.5213.7

EBITDA before other income, Screener (INR Cr)

41444736

PBILDT per CARE (INR Cr)

4144474.049.62

Depreciation & amortisation (INR Cr)

9976.979.76

Operating income / EBIT before other income (INR Cr)

32.036.240.1-3.8-4.0

Other income (INR Cr)

16155829.587.45

Finance costs (INR Cr)

0.390.340.210.412.63

Profit before tax (INR Cr)

47.3050.7497.2925.230.52

Tax expense (INR Cr)

11.914.621.878.032.02

Net income / PAT (INR Cr)

35.2636.1875.4217.20-1.49

EPS basic (INR)

61.7863.39132.1530.14-2.62

EPS diluted (INR)

61.7863.39132.1530.14-2.62

Dividend per share (INR)

9911.555

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

63.363.765.166.465.9

EBITDA margin before other income, Screener (%)

13.112.913.00.91.7

PBILDT margin per CARE (%)

13.112.913.01.172.88

Operating (EBIT) margin (%)

10.210.611.1-1.1-1.2

PBT margin (%)

15.114.926.87.30.2

Net margin (%)

11.210.620.85.0-0.4

Effective tax rate (%)

25.428.722.531.8384.8

Valuation Snapshot

MetricValueBasis

Revenue CAGR FY22–FY26 (4 years)

1.6%

313.51 → 333.60

Revenue CAGR FY21–FY26 (5 years)

6.2%

247.45 → 333.60 (FY21 was a COVID trough)

Revenue CAGR FY16–FY26 (10 years)

about 0%

[Screener]

TTM revenue (Q2 FY26–Q1 FY27)

INR 364.3 crore (+11% vs FY26)

[Screener; Q1 FY27 results]

TTM PAT

INR 22.57 crore

[Screener; VRO]

Share price

INR 790

[Screener], 12 Oct 2026

Market capitalisation

INR 451 crore

[Screener]

52-week high / low

INR 932 / 580 (ICICI: 903 / 579.90)

[Screener; ICICI Direct]

All-time high / low

INR 1,753.95 / INR 263.00

[ICICI Direct]

Shares outstanding

5.707 million

[Q1 FY27 results]

Free float

About 37.8%

100 − 62.23

Liquidity

Thin (example session volume about 4,300 shares on NSE)

[ICICI Direct]

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations (INR Cr)

70.5787.289.985.86101.34

Operating profit before other income (INR Cr)

-11311311

OPM (%)

-152.9123.210

Other income (INR Cr)

22.04-212-24.8427.96

PBT (INR Cr)

8.44-320-25.2335.79

PAT (INR Cr)

7.94-3.3015.30-21.4332.00

EPS (INR)

13.91-5.7826.81-37.5656.07

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

401423498511519

Net fixed assets (INR Cr)

88808399100

Capital work-in-progress (INR Cr)

137221

Investments (INR Cr)

183193273260243

Other assets incl. inventory, receivables, cash (INR Cr)

130148135151155

Total borrowings (INR Cr)

6531230

Other liabilities (INR Cr)

11610611210798

Share capital (INR Cr)

5.715.715.715.715.71

Reserves (INR Cr)

274306377387386

Shareholders' equity (INR Cr)

280312383393392

Book value per share (INR)

490546671688686

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operations (INR Cr)

401146-28-8

Cash from investing (INR Cr)

-40-5-3323-4

Cash from financing (INR Cr)

-2-6-8012

Free cash flow per Screener (INR Cr)

32635-43-36

Implied capex (CFO minus FCF, INR Cr)

85111528

CFO / operating profit (%)

12959131-629-47

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%)

13.412.221.74.4-0.4

ROA on average assets (%)

9.58.816.43.4-0.3

ROCE per Screener (%)

17172861

Debt / equity (x)

0.020.020.010.030.08

Interest coverage, (PBT + interest) / interest (x)

122150464621.2

PBILDT / interest per CARE (x)

1051292247.393.31

Asset turnover, revenue / average assets (x)

0.850.830.790.690.65

Debtor days

2932302937

Inventory days

124149126201187

Payable days

969598118104

Cash conversion cycle (days)

578758112120

Revenue by Region

MetricFY2024FY2025FY2026

Total revenue from operations, all geographies (INR Cr)

362.46345.77333.60

Share Price & Returns

HorizonStock price CAGR / return

1 year

−1%

3 years (CAGR)

−2%

5 years (CAGR)

+5%

10 years (CAGR)

+9%

Valuation Multiples

MultipleAlbert DavidPeer reference (VRO, Aug 2026)

P/E on TTM PAT of INR 22.57 crore (x)

20.0

Pfizer 29.3; Caplin 28.7; Eris 28.4; AstraZeneca 104.7

P/B (x)

1.15

Pfizer 4.9; Caplin 5.1; Eris 4.5

Enterprise value (INR Cr)

about 222 (451 market cap + 30 debt − 259 liquidity)

—

EV / Sales TTM (x)

0.61—

EV / EBITDA TTM, operating EBITDA about INR 27 crore (x)

about 8.2

—

P/E excluding treasury income (x)

Not meaningful (core operations roughly breakeven on a TTM basis after tax)

—

Dividend yield (%)

0.63

[Screener]

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

9911.555

Payout ratio per Screener (%)

1514917-192

Credit Ratings

AgencyFacilityRatingOutlookDate

CARE Ratings

Long-term bank facilities: cash credit INR 47.00 crore; forward contract INR 3.50 crore

CARE A

Negative

2 Jul 2026

CARE Ratings

Long-term / short-term bank facilities: bank guarantee INR 11.00 crore; letter of credit INR 1.00 crore

CARE A / CARE A1

Negative

2 Jul 2026

CARE rating history

Same facilities

A (Stable) on 6 Sep 2023 and 4 Jul 2024 → A (Negative) on 25 Jun 2025 → A (Negative) on 2 Jul 2026

——

Moody's / S&P / Fitch

—

Not rated

——

Analyst Conclusions

Management guidance

No quantitative guidance is published. Qualitatively, management says the FY25–FY26 field-force investments were made to support future growth, and the Board has given new CEO Amit Mahla a five-year mandate. CARE expects lower operating margins in FY27, which is why the outlook is Negative, although Q1 FY27 already exceeded that expectation.

Consensus expectations

None (no sell-side coverage).

Bull case

  1. The operating inflection is real. Q1 FY27 revenue of INR 101.3 crore (+43.6% YoY) is the highest quarter in the dataset, OPM recovered to about 10%, and employee costs fell 10% YoY. If the run-rate holds, FY27 revenue could exceed INR 400 crore with high-single-digit to low-double-digit operating margins, restoring core earnings to the FY22–FY24 level of about INR 30–35 crore before treasury income.

  2. Asymmetric valuation. At about INR 451 crore market cap, with about INR 259 crore of liquidity and INR 100 crore of net fixed assets, investors pay about 0.6x EV/Sales for a business with 65%+ gross margins and a unique, patent-protected flagship. A return to a 12–13% OPM at 1.5–2.0x EV/Sales would imply substantial upside.

  3. Optionality from idle capital. The INR 225 crore liquid investment book could fund brand acquisitions or in-licensing that fix the scale problem. A transformation-oriented CEO from Cipla, Sun and JB raises the probability of portfolio action.

Bear case

  1. Treasury-driven earnings. About 78% of Q1 FY27 PBT and the whole of TTM profitability depend on other income. Core operating EBIT was negative in FY25 and FY26. One quarter of strong sales does not establish a trend, especially after a −21% YoY quarter (Q1 FY26) made the base unusually low.

  2. Structural sub-scale and concentration. At INR 334–364 crore of revenue, a national prescription-promotion model is uneconomic. The top five products are 45% of sales and Placentrex alone is 26%. Any regulatory or scientific challenge to placental extracts would be existential for profitability.

  3. Governance and execution risk. Leadership churn (CEO exit, a five-month vacancy, plant and cluster heads resigning), a Negative credit outlook, negative operating cash flow for two years, a 120-day cash conversion cycle, no investor communication and only about 2% institutional ownership leave minority shareholders with low visibility and no catalyst for capital-allocation discipline.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
Mid-Nov 2026Q2 FY27 resultsRevenue above INR 95 crore and OPM above 8% would confirm the turnaround; other-income dependence
Feb 2027Q3 FY27 resultsSustained YoY growth against a tougher base (Q3 FY26 revenue INR 89.9 crore)
May 2027FY27 audited results and dividendFull-year core EBITDA; CFO turning positive; inventory days
Jun–Jul 2027CARE annual surveillanceOutlook revision to Stable (positive) or downgrade (negative)
OngoingCEO strategy articulationInvestor communication, portfolio rationalisation, M&A or in-licensing using cash reserves
OngoingPlacentrexIIT Kharagpur data, new indications or exports; any regulatory commentary on placental products
OngoingCapexPurpose of the INR 21 crore CWIP; revised Schedule M compliance
OngoingTreasuryInvestment-book composition and mark-to-market sensitivity
OngoingFootprintStatus of the Mandideep and Kalyani units (possible asset monetisation)

Concluding analyst verdict

Albert David Limited is a company of two balance sheets and one problem. The first balance sheet is a fortress: about INR 259 crore of cash and liquid investments, almost no debt, an A-category credit rating and 88 years of brand heritage anchored by Placentrex, a unique, process-patented placental-extract franchise with no direct domestic competitor and gross margins near 66%. The second is an operating business that, over FY25–FY26, failed to earn its cost of capital. The FY24-era field-force expansion added cost without revenue, so revenue fell in two successive years, operating margins dropped from 13% to roughly 1–2%, working capital ballooned, and the company recorded its first annual net loss in the period reviewed. The problem linking them is scale: a business of INR 330–360 crore cannot support national prescription promotion, so treasury income, not pharmaceuticals, has been the swing factor in earnings.

The Q1 FY27 print is the most encouraging datapoint in three years. Revenue grew 43.6%, operating margin recovered to about 10% and employee costs fell. It coincides with a credible new CEO who has large-company transformation experience. At about 0.6x EV/Sales and 1.15x book, the market is pricing in permanent stagnation, which makes the risk-reward skewed favourably if the recovery proves durable.

The evidence remains thin, though: one quarter, against an abnormally weak base, with treasury gains still providing most of the profit. Disclosure is poor, institutional sponsorship is negligible, the credit outlook is Negative, and governance sits firmly with the promoter family.

Verdict: a deep-value, special-situation turnaround candidate rather than a quality compounder. It merits close monitoring through the Q2–Q3 FY27 results and CARE's 2027 review. Conviction should rise only if core operating EBITDA margins sustain above 10%, operating cash flow turns positive, and management articulates a capital-allocation plan for the idle cash, ideally inorganic scale-building in its niche therapies.


  • Employee headcount and three-year trend

  • R&D expenditure (absolute and % of revenue), patent count and patent number for Placentrex

  • Domestic vs export revenue split and any regional breakdown

  • Brand-level revenue other than Placentrex; therapeutic positioning of several historical brands

  • Itemised executive remuneration for FY26 and FY27 (A.K. Kothari, Amit Mahla)

  • Board committee composition at October 2026

  • Top-10 named shareholders

  • Current operating status of the Mandideep and Kalyani units

  • Subject and outcome of the July 2026 postal ballot

  • Contingent liabilities and any tax disputes in the annual report notes

  • Exact DPS for FY22–FY23 (derived values shown)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground

Arun Kumar (A.K.) Kothari

Executive Chairman (Whole-time Director)

Long-standing; re-appointed at the 86th AGM (Aug 2025)

Son of the late G.D. Kothari, founder of the G.D. Kothari Group (tea, textiles, pharma, chemicals, engineering, property) [CARE Jul-26]

Amit Mahla

Whole-time Director & CEO (CARE calls him "Managing Director")

CEO since 12 May 2026; WTD from 19 Jun 2026 to 18 Jun 2031

28+ years in Indian pharma, with senior roles at Cipla, Sun Pharma and JB Pharma; experience in business transformation and portfolio integration [Board outcome; FilingReader]

Ranadeep Bhattacharya

Chief Financial Officer

In role per AR FY25

—

Lalit Lohia

Company Secretary & Compliance Officer

In role at the Aug 2025 AGM

Succeeded A.B.

Adijyoti Chattopadhyay

Corporate Head — HR

Per AR FY25

—

Dr. Kuntal Ganguly

Head — R&D

Per AR FY25

—

Santanu Bhattacharya

Plant Head, Kolkata

Per AR FY25

—

Chandra Bhushan Thakur

Head — Operations, Ghaziabad (per AR FY25)

A Ghaziabad operations head resigned 31 May 2026; whether this was Thakur is not confirmed

—

Saikath Banerjee

Cluster Head

Resignation accepted 4 Jul 2026

—

“—” = not publicly disclosed.

Board of Directors

DirectorCategoryNotes

Arun Kumar Kothari

Executive Chairman, Promoter

Chair and executive roles combined

Amit Mahla

Whole-time Director & CEO

From 19 Jun 2026

Prabhawati Devi Kothari

Non-Executive, Promoter group

[AR FY25]

Anand Vardhan Kothari

Non-Executive, Promoter group

[AR FY25]

Anurag Singhi

Independent Director

[AR FY25]

Shourya Sengupta

Independent Director

[AR FY25]

Dr. Monjori Mitra

Independent Director (woman director)

[AR FY25]

Naresh Pachisia

Independent Director

14 Nov 2024 – 13 Nov 2029

Dr. Rajiv Anant Desai

Independent Director

2 Aug 2025 – 1 Aug 2030

Board & Management Changes

DateChangeContext

14 Nov 2024

Naresh Pachisia joins as ID

Board refresh

2 Aug 2025

Dr. Rajiv Anant Desai joins as ID; A.K. Kothari re-appointed Executive Chairman

86th AGM / Board meeting

18 Dec 2025

MD & CEO Umesh Kunte resigns

Followed two years of margin compression after his expansion strategy

12 May 2026

Amit Mahla becomes CEO

Turnaround mandate

31 May 2026

Ghaziabad operations head resigns

Plant leadership transition

19 Jun 2026

Mahla elevated to WTD & CEO for five years

Ratified at the 87th AGM, 6 Aug 2026

4 Jul 2026

Cluster Head Saikath Banerjee resigns

Sales organisation restructuring

Shareholding Trend

Holder categorySep 2025 (%)Dec 2025 (%)Mar 2026 (%)Jun 2026 (%)

Promoters and promoter group

62.2362.2362.2362.23

Foreign institutional investors

0.600.600.580.57

Domestic institutional investors

1.651.651.651.63

Public

35.5035.5135.5235.56

Number of shareholders

14,66613,96713,55513,155

Competitive Landscape

Competitors by Segment

Business lineNamed competitorsPositioning vs Albert David

Placental extract / tissue repair

No direct domestic human-placenta competitor (per CARE). Indirect substitutes: growth-factor and collagen-based wound-care products, hyaluronic-acid injectables, NSAIDs and anti-inflammatories from Sun Pharma, Cipla, Mankind, Abbott India, Alkem, Intas

Albert David holds a near-monopoly in its exact molecule, but the therapy faces evidence-based scepticism and substitution by modern wound-care products

IV fluids / LVPs

Baxter India, B. Braun Medical India, Fresenius Kabi India, Otsuka (Claris Otsuka), Aculife Healthcare (Nirma), Amanta Healthcare, Denis Chem Lab, Parenteral Drugs (India)

Albert David is a sub-scale regional player; competitors have far larger capacity and tender reach

Herbal hepatoprotectives / adaptogens

Himalaya Wellness (Liv.52), Dabur, Charak Pharma, Zandu (Emami)

Adliv and Siotone are niche brands against dominant category leaders

Vitamins / nutrition

Mankind, Abbott India, Sun Pharma, Alkem, Pfizer India

Highly fragmented; Albert David is a small player

Anti-leishmanial (SSG)

Gland Pharma and other WHO-prequalified suppliers; alternatives such as liposomal amphotericin B (Gilead's AmBisome), miltefosine

Narrow, tender-driven niche

Listed small/mid-cap branded-pharma peers (valuation reference)

Pfizer Ltd, Caplin Point Laboratories, Eris Lifesciences, AstraZeneca Pharma India, Lincoln Pharmaceuticals, Kopran, Bliss GVS

Peer valuation and return benchmarks

Peer Comparison FY2026

MetricAlbert DavidPfizer LtdCaplin Point LabsEris Lifesciences

Market cap (28 Aug 2026)

51321,50119,12518,253

Revenue, TTM

3642,5702,2873,230

Net profit, TTM

22.57735.15678.07666.92

Net margin (%)

5.9726.8828.1020.60

ROE (%)

5.7519.1619.7318.75

P/E (x)

22.7429.2528.7428.35

P/B (x)

1.214.885.084.51

FY26 EBITDA

5.74904.18646.931,017.20

FY26 operating revenue

333.602,519.651,937.472,893.64

FY26 EBITDA margin (%)

1.735.933.435.2

Company Snapshot

$38.5M

Revenue

1938

Founded

Kolkata, India

Headquarters

SWOT Analysis

Strengths

  • Unique, patent-protected flagship: Placentrex is the only indigenously researched human-placenta product in India, has a process patent, and made up 26% of FY26 revenue [CARE Jul-26].
  • High gross margins: 65.9% in FY26 and 66.4% in FY25 [SA], well above typical small-cap formulators.
  • Fortress liquidity: INR 259.15 crore of cash, fixed deposits, mutual funds and bonds at 31 Mar 2026; gearing 0.08x; no term debt for six years [CARE Jul-26].
  • Investment-grade credit: CARE A / A1, reaffirmed July 2026, with a current ratio of 2.11x.
  • Diversified customers: no customer above 5%; top five at 13% of FY26 sales [CARE Jul-26].
  • Global public-health credential: WHO-authorised SSG supplier [CARE Jul-26].
  • Consistent dividends: a dividend was paid even in the FY26 loss year (INR 5 per share) [AR FY26].

Weaknesses

  • Two consecutive years of revenue decline: −4.6% in FY25 and −3.5% in FY26 [AR FY25; AR FY26].
  • Operating margin collapse: from 13.0% (FY24) to 0.9% (FY25) and 1.7% (FY26) [Screener].
  • Earnings dominated by treasury income: about 78% of Q1 FY27 PBT came from other income, and other income swung by −INR 24.8 crore in Q4 FY26 [Q1 FY27 results].
  • Rising concentration: top-five products rose from 39% to 45% of sales in one year [CARE Jul-26].
  • Worsening working capital: the cash conversion cycle widened from 58 days (FY24) to 120 days (FY26), and CFO was negative for two years (−INR 28 crore and −INR 8 crore) [Screener].
  • Leadership churn: CEO resignation in December 2025, a five-month vacancy, and plant and cluster heads resigning in May–July 2026.
  • Limited disclosure: no earnings calls, investor presentations, segment or geographic split, or published R&D figures.

Opportunities

  • Operating turnaround under the new CEO: Q1 FY27 revenue was +43.6% with OPM at about 10% [Q1 FY27 results].
  • Geographic expansion: the field force already built in southern and western India could reach breakeven [CARE Jul-26].
  • Inorganic growth funded by idle cash: about INR 225 crore of liquid investments could buy brands or in-license products. This was a stated aim in AR FY22 and has not been executed.
  • Placentrex scientific validation (IIT Kharagpur) could support new indications and export registrations [AR FY26].
  • Hospital-sector growth could lift IV-fluid volumes, given the existing glass and FFS capacity at Ghaziabad.
  • Valuation re-rating: P/B of 1.15x vs peers at about 4.5–5x [VRO]. Closing even part of the profitability gap could re-rate the stock.

Threats

  • Credit outlook risk: the Negative outlook could become a downgrade if margins stay low [CARE Jul-26].
  • Regulation of biologic- and placenta-derived products (CDSCO scrutiny and ethics of human-tissue sourcing) would hit up to 26% of revenue.
  • Price competition from scaled IV-fluid makers (Baxter, B. Braun, Fresenius Kabi, Otsuka, Aculife).
  • Unhedged foreign-exchange exposure on imported glass, lactose and amino acids [CARE Jul-26].
  • Market volatility hitting the treasury book (INR 243 crore of investments), as shown in Q4 FY26.
  • Talent attrition in sales and plant leadership during the transition.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
20 May 2025 (approx.)FY25 audited results: revenue INR 345.77 crore (−4.6%), PBT INR 25.23 crore (−74%), PAT INR 17.20 croreConfirms the margin collapse from field-force investment
25 Jun 2025CARE reaffirms A/A1; outlook revised from Stable to NegativeFirst external red flag on the operating trajectory
4 Jul 202586th AGM notice: INR 5 dividend, re-appointment of A.K. Kothari, revised pay for the Chairman and MD & CEOGovernance continuity
2 Aug 2025Q1 FY26 results: PBT INR 8.44 crore vs a loss in Q4 FY25; revenue INR 70.6 crore (−21% YoY)Profit driven by other income; operating loss of about INR 11 crore
2 Aug 2025Dr. Rajiv Anant Desai appointed Additional (Independent) DirectorBoard refresh
2 Aug 202586th AGM held via VC/OAVM; all resolutions passed—
13 Aug 2025Postal ballot notice issued for Desai's appointment—
17 Sep 2025Postal ballot result: 99.98% in favour of Desai—
1 Oct 2025Trading window closed for Q2 FY26Routine
12 Nov 2025Q2 FY26 results: revenue INR 87.2 crore (−11.4% YoY), net loss of about INR 3.3 croreOperating margin positive (2.9%) but negative other income
18 Dec 2025MD & CEO Umesh Kunte resigns (personal reasons)Leadership vacuum; end of the expansion era
18 Dec 2025Board meeting heldLikely to handle the CEO transition and interim arrangements
5 Feb 2026Special window for re-lodgement of physical share transfers opens (SEBI circular); runs to 4 Feb 2027Routine compliance
11 Feb 2026Q3 FY26 results: revenue INR 89.9 crore (+8.2% YoY), PAT INR 15.30 crore, OPM about 12%; unmodified limited reviewFirst YoY revenue growth in five quarters
7 Apr 2026Q4 FY26 Reg. 74(5) compliance certificateRoutine
4 May 2026Board meeting intimation for FY26 results and dividend—
12 May 2026FY26 results: revenue INR 333.60 crore (−3.5%), PBT INR 0.52 crore, net loss INR 1.49 crore; Q4 loss INR 21.43 crore driven by −INR 24.8 crore other income; INR 5 final dividend recommendedFirst annual loss in the period reviewed
12 May 2026Amit Mahla takes over as CEOTurnaround leadership
31 May 2026Head of Operations, Ghaziabad plant, resignsExecution risk at the IV-fluid plant
19 Jun 2026Mahla appointed Additional Director and WTD & CEO for five years; Board meeting heldLong-term commitment to the new CEO
2 Jul 2026CARE reaffirms A (Negative) / A1; bank facilities reduced to INR 62.5 croreNegative outlook continues
3 Jul 2026Record date fixed for the INR 5 final dividend—
4 Jul 2026Cluster Head Saikath Banerjee resignsSales restructuring
13–14 Jul 2026FY26 Annual Report dispatched; 87th AGM notice—
27–28 Jul 2026Postal ballot notice (dated 22 Jul 2026) dispatched; newspaper reminders on physical share re-lodgement–
30 Jul 2026Shares go ex-dividend (INR 5)—
6 Aug 202687th AGM held via VC/OAVM—
6 Aug 2026Q1 FY27 results: revenue INR 101.34 crore (+43.6% YoY), PBT INR 35.79 crore, PAT INR 32.00 crore, EPS INR 56.07; shares rise about 5% to about INR 730–831 intradayStrongest quarter in the dataset; operating inflection
7 Aug 2026AGM voting results: all seven resolutions passed, including the dividend and the CEO appointment—
29 Aug 2026Minutes of the 87th AGM filed—
11 Sep 2026Third and fourth reminders on the physical-share re-lodgement window publishedRoutine
22 Sep 2026Trading window closed ahead of Q2 FY27 resultsQ2 FY27 results expected around mid-November 2026
6 Oct 2026Reg. 74(5) certificate for Jul–Sep 2026Routine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 3,135.1 Mn in FY2022 to INR 3,336 Mn in FY2026.
Albert David Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations3,135.13,415.63,624.63,457.73,336
Gross profit1,9862,1752,3612,2952,197

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Albert David — Directors' Report FY2025-26 (87th AR), via IIFL (indiainfoline.com)
  2. Albert David — Directors' Report FY2024-25 (86th AR), via Arihant Capital (arihantcapital.com)
  3. Annual Report 2024-25 (full text), Value Research (valueresearchonline.com)
  4. NSE integrated filing, FY26 results (12–13 May 2026) (nsearchives.nseindia.com)
  5. NSE filing, Q3 FY26 results (11 Feb 2026) (nsearchives.nseindia.com)
  6. NSE filing, 86th AGM outcome (2 Aug 2025) (nsearchives.nseindia.com)
  7. NSE filing, postal ballot notice (13 Aug 2025) (nsearchives.nseindia.com)
  8. NSE filing, disclosure (28 Jul 2026) (nsearchives.nseindia.com)
  9. BSE filing, postal ballot outcome (26 Dec 2024) (bseindia.com)
  10. CARE Ratings press release (2 Jul 2026) (careratings.com)
  11. ScanX, Q1 FY27 results and FY26 summary (scanx.trade)
  12. ScanX, CEO appointment (scanx.trade)
  13. FilingReader, Amit Mahla appointment (filingreader.com)
  14. FilingReader, FY26 results (filingreader.com)
  15. FilingReader, Q1 FY26 and Desai appointment (filingreader.com)
  16. FilingReader, postal ballot result (filingreader.com)
  17. FilingReader, 86th AGM notice (filingreader.com)
  18. Equitybulls, Q4 FY26 (equitybulls.com)
  19. Univest, Q1 FY27 (univest.in)
  20. Value Research, CEO resignation notice (valueresearchonline.com)
  21. Board Stewardship, Kunte resignation (boardstewardship.com)
  22. People Matters, Kunte appointment (peoplematters.in)
  23. Simply Wall St, management and compensation (simplywall.st)
  24. Screener.in, financials, shareholding and documents (screener.in)
  25. StockAnalysis.com, income statement (stockanalysis.com)
  26. Value Research, peer comparison (valueresearchonline.com)
  27. TheCompanyCheck, revenue history (thecompanycheck.com)
  28. ICICI Direct, share data (icicidirect.com)
  29. Zonebourse, corporate calendar (ch.zonebourse.com)
  30. Kotak Securities, company history (kotaksecurities.com)
  31. Arihant Capital, company history (arihantcapital.com)
  32. InvestYadnya, company profile (investyadnya.in)
  33. Medical Dialogues, company profile (medicaldialogues.in)
  34. Truemeds, product listings (truemeds.in)
  35. Vogue Stock / BFSL, location register (voguestock.in)
  36. AGM notice 2022 (auditor appointment) (financialfilings.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.